Leading financial firm Jefferies has maintained its positive outlook on Indian hospital stocks, advising investors to 'Buy' following a 15-20% market correction. The brokerage believes this dip, largely influenced by regulatory concerns over the pricing of consumables and oncology drugs, presents a compelling entry point for significant gains.
Jefferies has issued specific target prices for key players in the sector, anticipating potential upsides ranging from 22% to 46%. Among the recommendations, Apollo Hospitals Enterprise Ltd. received a target of Rs 10,350, Fortis Healthcare Ltd. Rs 1,125, and Max Healthcare Institute Ltd. Rs 1,260. Other companies singled out include Manipal Health Enterprises Ltd. with a target of Rs 870, Medanta Ltd. at Rs 1,660, and Dr. Agarwal's Healthcare at Rs 600.
Regulatory Concerns and Market Reaction
The recent market weakness in Indian hospital stocks stems from fears surrounding potential government intervention in the pricing of medical consumables and oncology drugs. These two categories collectively account for 15-20% of hospital revenues. Jefferies estimates that under various price-cap scenarios, and if hospitals are unable to offset the impact, earnings before interest, taxes, depreciation, and amortization (EBITDA) could be affected by 2-5%.
Reports indicate that the government is in discussions with the medical sector regarding rationalizing trade margins for medical devices and consumables. This follows observations of significant mark-ups—sometimes 10-20 times—on hospital items. Similarly, the Supreme Court has flagged a substantial price disparity in cancer drugs, questioning why a uniform 16% margin cap couldn't be applied across all pharmaceutical products.
Historical Precedent for Recovery
Despite these regulatory headwinds, Jefferies emphasizes that past instances of government intervention have historically created attractive buying opportunities. The brokerage points to previous price caps on stents (2017) and implants (2017), noting that while stock prices reacted negatively for three to six months, a recovery typically followed. For example, Apollo Hospitals delivered 3% returns in the second year after the stent and implant price caps were imposed.
Furthermore, hospitals have demonstrated resilience in mitigating the impact of price cuts. Following a 70-85% reduction in prices for cardiac stents and orthopedic knee implants nearly a decade ago, hospitals successfully offset the effects through staggered procedure price increases and cost-rationalization measures over 12-15 months. Apollo Hospitals, in particular, managed to restore its EBITDA margins to previous levels within a few quarters after similar steps in 2017-18.
Strong Fundamentals and Valuation
Jefferies reiterates that the underlying fundamentals of the Indian hospital sector remain robust, driven by strong demand for quality tertiary care beds. Post-correction, hospital stocks are trading at an implied 20-27 times FY28 EV/EBITDA valuation, a decrease from 25-35 times a year ago. For companies capable of delivering sustainable high-teen EBITDA growth, this correction is seen as an excellent entry point.
The firm ranks Fortis, Manipal, Apollo, Max Health, and Medanta as its preferred picks within the sector, signaling confidence in their ability to navigate regulatory changes and capitalize on the strong demand for healthcare services in India.